← Back to headlines
ImmunityBio (IBRX) Receives FDA Warning, BTIG Maintains Positive Outlook
ImmunityBio (IBRX) has been issued a warning by the FDA, though investment firm BTIG has indicated it will maintain a positive stance on the company's prospects.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Iloilo Reinstates Health Protocols Amid Extreme Heat
just now
Four arrested for selling P102 million in fake anti-cancer medicines in Makati
just now
Vigilance Urged After Death of Two Children in Abandoned Car
just now
Long Waiting Lists for Pediatric Eye Doctors in Latvia Lead to Unborn Child Registrations
just now